Dianzani C and others found that ICOS-Fc treatment inhibited tumor cell migration to the lungs in mice, increasing IL-17A and RAR-related orphan receptor C (RORc) expression while reducing IL-10 and Foxp3 expression. This evidence concerns the gene FOXP3 and neoplasm.